Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan") resulted in an increase in the notional allocation of Ordinary share ADRs. This transaction occurred on February 5, 2010, at a price of $38.06 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 5, 2010.
- Transaction Price: $38.06 per ADR.
- Involved Parties: Dr M M Slaoui (17 ADRs), Mr W C Louv (8 ADRs), and Dr D Pulman (13 ADRs).
- Plan Details: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs.
- Reporting Date: The notification was signed and dated February 9, 2010.